Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

The KEYNOTE-B96 study of pembrolizumab plus paclitaxel in recurrent platinum-resistant ovarian cancer has met its primary end ...

US pharma giant Merck & Co (NYSE: MRK) today announced that the Phase III KEYNOTE-B96 trial, also known as ENGOT-ov65, met ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...